Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
Waldenström's Macroglobulinemia (lymphoplasmacytic lymphoma, WM) remains incurable with
limited therapeutic options and notably absent FDA approved therapy with any WM indication.
Therefore, there is a need to identify new therapeutic agents for WM patients both in the
upfront and relapsed/refractory setting. The purpose of this research study is to assess the
efficacy of perifosine in patients with relapsed or refractory WM.